医疗器械行业的技术需求

D.T. Achord
{"title":"医疗器械行业的技术需求","authors":"D.T. Achord","doi":"10.1109/ELECTR.1996.501200","DOIUrl":null,"url":null,"abstract":"With fast-rising health-care costs, reimbursement and outcomes considerations are now key to the technology needs of new products in the medical device industry. Healthcare spending in the United States has grown from $280 billion in 1981 to $1 trillion in 1994, and accounts for 14% of the total gross domestic product. With healthcare costs now increasing at a rate of 4.9% per year, cost containment has become the dominant factor in healthcare policy. As a result, reimbursement has become as prominent an issue for the medical device industry as regulatory changes. For example, fee-for-service reimbursement is being replaced by capitation in many countries. Aggressive pricing has become so predominant in the U.S. private sector that in some instances fees are lower than federally funded Medicare reimbursement rates. It is argued that the irreversible movement to managed care is resulting in fewer, larger healthcare delivery organizations with stronger leverage in the marketplace. Diagnostic laboratories, in turn, are increasing compliance, centralizing laboratories, reducing costs, and increasing their use of automated instrumentation. Outcomes research is also becoming increasingly important in diagnostics. Managed care providers are using technology planning committees to continue their quest for diagnostic technologies which both improve outcomes and decrease costs. The technology needs of the medical device industry include products which will decrease the length of hospital stay, speed test turnaround time, reduce hospital labor, procedural costs, documentation, and scheduling time.","PeriodicalId":119154,"journal":{"name":"Professional Program Proceedings. ELECTRO '96","volume":"29 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Technology needs of the medical device industry\",\"authors\":\"D.T. Achord\",\"doi\":\"10.1109/ELECTR.1996.501200\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"With fast-rising health-care costs, reimbursement and outcomes considerations are now key to the technology needs of new products in the medical device industry. Healthcare spending in the United States has grown from $280 billion in 1981 to $1 trillion in 1994, and accounts for 14% of the total gross domestic product. With healthcare costs now increasing at a rate of 4.9% per year, cost containment has become the dominant factor in healthcare policy. As a result, reimbursement has become as prominent an issue for the medical device industry as regulatory changes. For example, fee-for-service reimbursement is being replaced by capitation in many countries. Aggressive pricing has become so predominant in the U.S. private sector that in some instances fees are lower than federally funded Medicare reimbursement rates. It is argued that the irreversible movement to managed care is resulting in fewer, larger healthcare delivery organizations with stronger leverage in the marketplace. Diagnostic laboratories, in turn, are increasing compliance, centralizing laboratories, reducing costs, and increasing their use of automated instrumentation. Outcomes research is also becoming increasingly important in diagnostics. Managed care providers are using technology planning committees to continue their quest for diagnostic technologies which both improve outcomes and decrease costs. The technology needs of the medical device industry include products which will decrease the length of hospital stay, speed test turnaround time, reduce hospital labor, procedural costs, documentation, and scheduling time.\",\"PeriodicalId\":119154,\"journal\":{\"name\":\"Professional Program Proceedings. ELECTRO '96\",\"volume\":\"29 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Professional Program Proceedings. ELECTRO '96\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1109/ELECTR.1996.501200\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Professional Program Proceedings. ELECTRO '96","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ELECTR.1996.501200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

随着医疗保健成本的快速上升,对医疗器械行业新产品技术需求的关键是考虑报销和结果。美国的医疗支出从1981年的2800亿美元增长到1994年的1万亿美元,占国内生产总值的14%。随着医疗保健成本以每年4.9%的速度增长,成本控制已成为医疗保健政策的主要因素。因此,报销已成为医疗器械行业与监管变化一样突出的问题。例如,在许多国家,按服务收费的偿还办法正在被按人头支付所取代。在美国私营部门,激进的定价已经变得如此普遍,以至于在某些情况下,费用低于联邦资助的医疗保险报销率。有人认为,向管理式医疗的不可逆转的运动正在导致更少、更大的医疗保健服务组织在市场上具有更强的杠杆作用。诊断实验室,反过来,正在提高合规性,集中实验室,降低成本,并增加自动化仪器的使用。结果研究在诊断学中也变得越来越重要。管理式医疗服务提供者正在利用技术规划委员会继续寻求既能改善结果又能降低成本的诊断技术。医疗器械行业的技术需求包括缩短住院时间、加快测试周转时间、减少医院人工、程序成本、文档和调度时间的产品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Technology needs of the medical device industry
With fast-rising health-care costs, reimbursement and outcomes considerations are now key to the technology needs of new products in the medical device industry. Healthcare spending in the United States has grown from $280 billion in 1981 to $1 trillion in 1994, and accounts for 14% of the total gross domestic product. With healthcare costs now increasing at a rate of 4.9% per year, cost containment has become the dominant factor in healthcare policy. As a result, reimbursement has become as prominent an issue for the medical device industry as regulatory changes. For example, fee-for-service reimbursement is being replaced by capitation in many countries. Aggressive pricing has become so predominant in the U.S. private sector that in some instances fees are lower than federally funded Medicare reimbursement rates. It is argued that the irreversible movement to managed care is resulting in fewer, larger healthcare delivery organizations with stronger leverage in the marketplace. Diagnostic laboratories, in turn, are increasing compliance, centralizing laboratories, reducing costs, and increasing their use of automated instrumentation. Outcomes research is also becoming increasingly important in diagnostics. Managed care providers are using technology planning committees to continue their quest for diagnostic technologies which both improve outcomes and decrease costs. The technology needs of the medical device industry include products which will decrease the length of hospital stay, speed test turnaround time, reduce hospital labor, procedural costs, documentation, and scheduling time.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信